A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Liver and Digestive Health

NCT07738744 | Completed

• 2 other identifiers: 20820legacy-20820
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the effects of Edenboost Alpha Cleanse, a dietary supplement, on symptoms associated with liver and digestive health. The study is a single-arm, open-label trial in which all 40 enrolled participants will use the test product daily for 12 weeks. Participants will complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and will undergo blood testing (hepatic function panel) at Baseline and Week 12. Primary outcomes focus on changes in liver function biomarkers, while secondary outcomes capture participants' self-reported experiences of energy levels, abdominal bloating, abdominal pain, fatigue, and nausea.

Conditions

Liver Health; Digestive Health; Fatigue; Abdominal Bloating; Abdominal Pain; Nausea; Energy Levels

Outcome Measures

Primary Outcomes (6)

• Change in Alanine Aminotransferase (ALT/SGPT)

  Change in serum ALT/SGPT level assessed via hepatic function panel blood test at Labcorp

  Baseline and Week 12

• Change in Albumin

  Change in serum albumin level assessed via hepatic function panel blood test at Labcorp

  Baseline and Week 12

• Change in Alkaline Phosphatase

  Change in serum alkaline phosphatase level assessed via hepatic function panel blood test at Labcorp

  Baseline and Week 12

• Change in Aspartate Aminotransferase (AST/SGOT)

  Change in serum AST/SGOT level assessed via hepatic function panel blood test at Labcorp

  Baseline and Week 12

• Change in Bilirubin

  Change in serum bilirubin level assessed via hepatic function panel blood test at Labcorp

  Baseline and Week 12

• Change in Total Protein

  Change in serum total protein level assessed via hepatic function panel blood test at Labcorp

  Baseline and Week 12

Secondary Outcomes (5)

• Change in Self-Reported Abdominal Bloating

  Baseline, Week 4, Week 8, and Week 12

• Change in Self-Reported Abdominal Pain

  Baseline, Week 4, Week 8, and Week 12

• Change in Self-Reported Fatigue

  Baseline, Week 4, Week 8, and Week 12

• Change in Self-Reported Nausea

  Baseline, Week 4, Week 8, and Week 12

• Change in Self-Reported Energy Levels

  Baseline, Week 4, Week 8, and Week 12

Study Arms (1)

Edenboost Alpha Cleanse

EXPERIMENTAL

Dietary Supplement: Edenboost Alpha Cleanse

Interventions

Edenboost Alpha Cleanse DIETARY_SUPPLEMENT

All participants receive Edenboost Alpha Cleanse (two capsules once daily with the first meal of the day) for 12 weeks.

Edenboost Alpha Cleanse

Eligibility Criteria

• Age: 40 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be male or female.
• Be aged 40-65.
• Anyone who has struggled with low energy levels and fatigue over the past four weeks.
• Anyone who has struggled with at least two of the following symptoms over the past four weeks: abdominal bloating, abdominal discomfort, constipation, diarrhea, digestive discomfort.
• Willing to maintain the same diet, sleep pattern, and exercise regimen consistently throughout the study duration.
• If taking any other supplements, medications, or herbal remedies, has been doing so consistently for at least three months and is willing to maintain this routine for the duration of the trial.
• Willing to avoid introducing any other supplements, medications, or herbal remedies for the duration of the trial.
• Resides in the United States.

You may not qualify if:

• Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including mental health disorders, a history of serious illness in the last three months, a history of substance abuse, or planned surgery during the study period.
• Anyone with a known history of severe digestive disorders like acid reflux, peptic ulcers, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), GI bleeding, Crohn's disease, Ulcerative Colitis (UC), or gastrointestinal tract surgeries.
• Anyone with a history of kidney stones.
• Anyone with any allergies or sensitivities to any of the study product ingredients.
• Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
• Anyone on Coumadin (warfarin) or antiplatelet therapy (e.g., Plavix (clopidogrel), aspirin).
• Anyone with uncontrolled chronic disease, including but not limited to diabetes, hypertension (high blood pressure), and thyroid-related conditions.
• Anyone unwilling to follow the study protocol.
• Anyone who is currently a smoker or has been a smoker in the past 3 months.
• Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration.

Sponsors & Collaborators

• Edenboost: lead
• Citruslabs: collaborator

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89118, United States

Location

MeSH Terms

Conditions

Fatigue; Abdominal Pain; Nausea

Condition Hierarchy (Ancestors)

Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Pain; Neurologic Manifestations; Signs and Symptoms, Digestive

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2026
• First Posted: July 31, 2026
• Study Start: November 17, 2025
• Primary Completion: January 15, 2026
• Study Completion: January 15, 2026
• Last Updated: July 31, 2026

Record last verified: 2026-07

Locations

US (1)